This prospective study explored the relationship between expression of AKR1B10 mRNA and various clinical parameters in non-small-cell lung cancer (NSCLC) in terms of its validation as a marker for NSCLC. Tumour tissue samples were collected from 229 patients with NSCLC. Tissue samples from adjacent non-malignant lung tissue (> 5 cm from the tumour) of 89 of these patients and samples from 20 patients with benign lung disease were used as controls. Quantitative reverse transcription–polymerase chain reaction showed significantly higher levels of AKR1B10 mRNA expression in NSCLC tumour tissue than in adjacent non-malignant lung tissue and benign lung tissue. Statistically significant factors for AKR1B10 mRNA over-expression were found to be male gender, smoking, squamous cell carcinoma and moderate or poor cell differentiation. It is concluded that AKR1B10 seems to have potential as a prognostic marker for NSCLC and warrants further investigation.
ParkinDMBrayFIDevesaSS: Cancer burden in the year 2000. The global picture. Eur J Cancer2001; 37 (suppl 8): S4–S66.
2.
WingoPARiesLAGiovinoGA: Annual report to the nation on the status of cancer, 1973–1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst1999; 91: 675–690.
3.
CarneyDN: Lung cancer–time to move on from chemotherapy. N Engl J Med2000; 346: 126–128.
4.
KimBLeeHJChoiHY: Clinical validity of the lung cancer biomarkers identified by bioinformatics analysis of public expression data. Cancer Res2007; 67: 7431–7438.
5.
CaoDFanSTChungSS: Identification and characterization of a novel human aldose reductase-like gene. J Biol Chem1998; 273: 11429–11435.
6.
ScuricZStainSCAndersonWF: New member of aldose reductase family proteins overexpressed in human hepatocellular carcinoma. Hepatology1998; 27: 943–950.
7.
FukumotoSYamauchiNMoriguchiH: Overexpression of the aldo-keto reductase family protein AKR1B10 is highly correlated with smokers' non-small cell lung carcinomas. Clin Cancer Res2005; 11: 1776–1785.
8.
YoshitakeHTakahashiMIshikawaH: Aldo-keto reductase family 1, member B10 in uterine carcinomas: A potential risk factor of recurrence after surgical therapy in cervical cancer. Int J Gynecol Cancer2007; 17: 1300–1306.
9.
MaJYanRZuX: Aldo-keto reductase family 1 B10 affects fatty acid synthesis by regulating the stability of acetyl-CoA carboxylase-α in breast cancer cells. J Biol Chem2008; 283: 3418–3423.
10.
NagarajNSBeckersSMensahJK: Cigarette smoke condensate induces cytochromes P450 and aldo-keto reductases in oral cancer cells. Toxicol Lett2006; 165: 182–194.
11.
LiCPGotoAWatanabeA: AKR1B10 in usual interstitial pneumonia: Expression in squamous metaplasia in association with smoking and lung cancer. Pathol Res Pract2008; 204: 295–304.
12.
HsuNYHoHCChowKC: Overexpression of dihydrodiol dehydrogenase as a prognostic marker of non-small cell lung cancer. Cancer Res2001; 61: 2727–2731.
13.
GallegoOBelyaevaOVPorteS: Comparative functional analysis of human medium-chain dehydrogenases, short-chain dehydrogenases/reductases and aldo-keto reductases with retinoids. Biochem J2006; 399: 101–109.
14.
SpiteMBabaSPAhmedY: Substrate specificity and catalytic efficiency of aldo-keto reductases with phospholipid aldehydes. Biochem J2007; 405: 95–105.
15.
BlanerWSOlsonJA: Retinol and retinoic acid metabolism. In: The Retinoid: Biology, Chemistry, and Medicine, 2nd edn (SpornMBRobertsABGoodmanDS, eds). New York: Raven Press, 1999; pp 229–255.
16.
CrosasBHyndmanDJGallegoO: Human aldose reductase and human small intestine aldose reductase are efficient retinal reductases: Consequences for retinoid metabolism. Biochem J2003; 373: 973–979.
17.
Vander JagtDLHunsakerLARobinsonB: Aldehyde and aldose reductases from human placenta. Heterogeneous expression of multiple enzyme forms. J Biol Chem1990; 265: 10912–10918.
18.
MartinHJBreyer-PfaffUWsolV: Purification and characterization of AKR1B10 from human liver: Role in carbonyl reduction of xenobiotics. Drug Metab Dispos2006; 34: 464–470.
19.
Zeindl-EberhartEKlugbauerSDimitrijevicN: Proteome analysis of rat hepatomas: Carcinogen-dependent tumor-associated protein variants. Electrophoresis2001; 22: 3009–3018.
20.
Zeindl-EberhartEHaraidaSLiebmannS: Detection and identification of tumor-associated protein variants in human hepatocellular carcinomas. Hepatology2004; 39: 540–549.
21.
PenningTM: AKR1B10: A new diagnostic marker of non-small cell lung carcinoma in smokers. Clin Cancer Res2005; 11: 1687–1690.
22.
WoenckhausMKlein-HitpassLGrepmeierU: Smoking and cancer-related gene expression in bronchial epithelium and non-small-cell lung cancers. J Pathol2006; 210: 192–204.
23.
YanRZuXMaJ: Aldo-keto reductase family 1 B10 gene silencing results in growth inhibition of colorectal cancer cells: Implication for cancer intervention. Int J Cancer2007; 121: 2301–2306.
24.
GallegoORuizFXArdèvolA: Structural basis for the high all-trans-retinaldehyde reductase activity of the tumor marker AKR1B10. Proc Natl Acad Sci USA2007; 104: 20764–20769.
